Cancers, Vol. 12, Pages 1277: Cancer During Pregnancy: The Role of Vascular Toxicity in Chemotherapy-Induced Placental Toxicity Cancers doi: 10.3390/cancers12051277 Authors: Bar-Joseph Peccatori Goshen-Lago Cribiù Scarfone Miller Nemerovsky Levi Shalgi Ben-Aharon Breast cancer is diagnosed in ~0.3% of pregnant women. Studies that have addressed gestational and neonatal outcomes of chemotherapy during pregnancy have demonstrated increased gestational...
Mon May 18, 2020 03:00
Cancers, Vol. 12, Pages 1274: Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma Cancers doi: 10.3390/cancers12051274 Authors: Naoshi Nishida Masatoshi Kudo Immunotherapies are promising approaches for treating hepatocellular carcinomas (HCCs) refractory to conventional therapies. However, a recent clinical trial of immune checkpoint inhibitors (ICIs) revealed that anti-tumor responses to ICIs are not satisfactory in HCC cases. Therefore,...
Mon May 18, 2020 03:00
Cancers, Vol. 12, Pages 1278: Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors Cancers doi: 10.3390/cancers12051278 Authors: Kasun Wanigasooriya Robert Tyler Joao D. Barros-Silva Yashashwi Sinha Tariq Ismail Andrew D. Beggs Radiotherapy is routinely used as a neoadjuvant, adjuvant or palliative treatment in various cancers. There is significant variation in clinical response to...
Mon May 18, 2020 03:00
Cancers, Vol. 12, Pages 1273: Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer Cancers doi: 10.3390/cancers12051273 Authors: Rajani Rai Kathleen Gong Essel Doris Mangiaracina Benbrook Justin Garland Yan Daniel Zhao Vishal Chandra Sulforaphane exerts anti-cancer activity against multiple cancer types. Our objective was to evaluate utility of sulforaphane for endometrial cancer therapy. Sulforaphane...
Mon May 18, 2020 03:00
Cancers, Vol. 12, Pages 1275: Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients Cancers doi: 10.3390/cancers12051275 Authors: Duda Dima Cucu Sorop Klein Ancukiewicz Kitahara Iacob Bacalbasa Tomescu Herlea Tanase Croitoru Popescu Background: Improving surgical outcomes in hepatocellular carcinoma (HCC) patients would greatly benefit from biomarkers. Angiogenesis...
Mon May 18, 2020 03:00
Cancers, Vol. 12, Pages 1276: Evaluation of a Novel Liquid Fiducial Marker, BioXmark®, for Small Animal Image-Guided Radiotherapy Applications Cancers doi: 10.3390/cancers12051276 Authors: Kathryn H. Brown Mihaela Ghita Giuseppe Schettino Kevin M. Prise Karl T. Butterworth BioXmark® (Nanovi A/S, Denmark) is a novel fiducial marker based on a liquid, iodine-based and non-metallic formulation. BioXmark® has been clinically validated and reverse translated to...
Mon May 18, 2020 03:00
Cancers, Vol. 12, Pages 1271: Serological Biomarkers for Early Detection of Hepatocellular Carcinoma: A Focus on Autoantibodies against Tumor-Associated Antigens Encoded by Cancer Driver Genes Cancers doi: 10.3390/cancers12051271 Authors: Keyan Wang Miao Li Jiejie Qin Guiying Sun Liping Dai Peng Wang Hua Ye Jianxiang Shi Lin Cheng Qian Yang Cuipeng Qiu Di Jiang Xiao Wang Jianying Zhang Substantial evidence manifests the occurrence of autoantibodies...
Mon May 18, 2020 03:00
Cancers, Vol. 12, Pages 1272: Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs Cancers doi: 10.3390/cancers12051272 Authors: Laura Marconato Silvia Sabattini Giorgia Marisi Federica Rossi Vito Ferdinando Leone Andrea Casadei-Gardini Unresectable nodular and diffuse hepatocellular carcinoma (HCC) have a poor prognosis with limited treatment options. Systemic traditional chemotherapy has been only rarely...
Mon May 18, 2020 03:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.